Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mirati Therapeutics appoints Joseph Leveque Chief Medical Officer » 16:17
05/18/20
05/18
16:17
05/18/20
16:17
MRTX

Mirati Therapeutics

$106.10 /

+2.72 (+2.63%)

Mirati Therapeutics…

Mirati Therapeutics announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18. Isan Chen, M.D., will step down as Chief Medical and Development Officer to lead an early-stage biotech company, however, Dr. Chen will continue to act as an advisor to Mirati.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$106.10 /

+2.72 (+2.63%)

MRTX Mirati Therapeutics
$106.10 /

+2.72 (+2.63%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 JPMorgan
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential
05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
MRTX Mirati Therapeutics
$106.10 /

+2.72 (+2.63%)

MRTX Mirati Therapeutics
$106.10 /

+2.72 (+2.63%)

MRTX Mirati Therapeutics
$106.10 /

+2.72 (+2.63%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call » 12:25
05/18/20
05/18
12:25
05/18/20
12:25
JNJ

Johnson & Johnson

$150.82 /

+0.53 (+0.35%)

, LLY

Eli Lilly

$158.39 /

-1.02 (-0.64%)

, MRTX

Mirati Therapeutics

$108.08 /

+4.7 (+4.55%)

, AMGN

Amgen

$237.35 /

-2.78 (-1.16%)

Biotech Analysts discuss…

Biotech Analysts discuss KRAS target in Oncology on an Analyst/Industry conference call to be held on May 18 at 1 pm.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$108.08 /

+4.7 (+4.55%)

LLY Eli Lilly
$158.39 /

-1.02 (-0.64%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

AMGN Amgen
$237.35 /

-2.78 (-1.16%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
04/28/20 UBS
Johnson & Johnson downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$158.39 /

-1.02 (-0.64%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
MRTX Mirati Therapeutics
$108.08 /

+4.7 (+4.55%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 JPMorgan
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential
05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
AMGN Amgen
$237.35 /

-2.78 (-1.16%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
05/01/20 Wells Fargo
Amgen price target raised to $237 from $220 at Wells Fargo
MRTX Mirati Therapeutics
$108.08 /

+4.7 (+4.55%)

LLY Eli Lilly
$158.39 /

-1.02 (-0.64%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

AMGN Amgen
$237.35 /

-2.78 (-1.16%)

MRTX Mirati Therapeutics
$108.08 /

+4.7 (+4.55%)

LLY Eli Lilly
$158.39 /

-1.02 (-0.64%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

AMGN Amgen
$237.35 /

-2.78 (-1.16%)

MRTX Mirati Therapeutics
$108.08 /

+4.7 (+4.55%)

LLY Eli Lilly
$158.39 /

-1.02 (-0.64%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

AMGN Amgen
$237.35 /

-2.78 (-1.16%)

JNJ Johnson & Johnson
$150.82 /

+0.53 (+0.35%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call » 09:09
05/18/20
05/18
09:09
05/18/20
09:09
JNJ

Johnson & Johnson

$150.29 /

+2.605 (+1.76%)

, LLY

Eli Lilly

$159.41 /

+1.1 (+0.69%)

, MRTX

Mirati Therapeutics

$103.38 /

+3.32 (+3.32%)

, AMGN

Amgen

$240.13 /

+3.74 (+1.58%)

Biotech Analysts discuss…

Biotech Analysts discuss KRAS target in Oncology on an Analyst/Industry conference call to be held on May 18 at 1 pm.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$103.38 /

+3.32 (+3.32%)

LLY Eli Lilly
$159.41 /

+1.1 (+0.69%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

AMGN Amgen
$240.13 /

+3.74 (+1.58%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
04/28/20 UBS
Johnson & Johnson downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$159.41 /

+1.1 (+0.69%)

04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
MRTX Mirati Therapeutics
$103.38 /

+3.32 (+3.32%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 JPMorgan
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential
05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
AMGN Amgen
$240.13 /

+3.74 (+1.58%)

05/11/20 Wedbush
MyoKardia price target raised to $127 from $90 at Wedbush
05/04/20 Cantor Fitzgerald
Amgen price target raised to $263 from $255 at Cantor Fitzgerald
05/01/20 BMO Capital
Amgen price target raised to $291 from $274 at BMO Capital
05/01/20 Wells Fargo
Amgen price target raised to $237 from $220 at Wells Fargo
MRTX Mirati Therapeutics
$103.38 /

+3.32 (+3.32%)

LLY Eli Lilly
$159.41 /

+1.1 (+0.69%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

AMGN Amgen
$240.13 /

+3.74 (+1.58%)

MRTX Mirati Therapeutics
$103.38 /

+3.32 (+3.32%)

LLY Eli Lilly
$159.41 /

+1.1 (+0.69%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

AMGN Amgen
$240.13 /

+3.74 (+1.58%)

MRTX Mirati Therapeutics
$103.38 /

+3.32 (+3.32%)

LLY Eli Lilly
$159.41 /

+1.1 (+0.69%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

AMGN Amgen
$240.13 /

+3.74 (+1.58%)

JNJ Johnson & Johnson
$150.29 /

+2.605 (+1.76%)

Earnings
Mirati Therapeutics reports Q1 EPS ($2.02) , consensus ($1.66) » 17:14
05/07/20
05/07
17:14
05/07/20
17:14
MRTX

Mirati Therapeutics

$93.30 /

+0.91 (+0.98%)

Reports Q1 revenue $300K,…

Reports Q1 revenue $300K, consensus $260K. "Despite the challenges many are facing related to the COVID-19 pandemic, we have continued to advance all of our clinical and preclinical programs. MRTX849, our selective KRAS G12C inhibitor program, is progressing according to plan including enrollment in the registration-enabling arm of the KRYSTAL Phase 1/2 clinical trial in patients with non-small cell lung cancer receiving 2nd or 3rd line therapy. We have also initiated combination trials of MRTX849 with pembrolizumab, cetuximab and TNO155," said CEO Charles Baum. "Today, we are also pleased to report updated overall survival data for our sitravatinib program. Our on-going Phase 2 trial of sitravatinib in combination with nivolumab - MRTX-500 -, continues to demonstrate durable efficacy. Preliminary median OS of 18.1 months was observed for the subset of patients who received the combination as their 2nd or 3rd line of therapy, which is the same profile of patients currently enrolling in SAPPHIRE, our global, randomized Phase 3 clinical trial. We look forward to presenting additional data from the MRTX-500 trial at a future medical conference."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$93.30 /

+0.91 (+0.98%)

05/01/20
Fly Intel: Top five analyst upgrades
05/01/20 JPMorgan
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential
05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
Upgrade
Fly Intel: Top five analyst upgrades » 10:09
05/01/20
05/01
10:09
05/01/20
10:09
BIG

Big Lots

$24.08 /

+0.62 (+2.64%)

, K

Kellogg

$65.20 /

-0.35 (-0.53%)

, WWW

Wolverine World Wide

$19.97 /

-0.6 (-2.92%)

, MRTX

Mirati Therapeutics

$85.04 /

+ (+0.00%)

, SGEN

Seattle Genetics

$147.05 /

+9.77 (+7.12%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Big Lots (BIG) upgraded to Overweight from Neutral at Piper Sandler with analyst Peter Keith saying after virtual investor meetings, the analyst believes Big Lots will be a long-term beneficiary exiting COVID-19. 2. Kellogg (K) upgraded to Equal Weight from Underweight at Consumer Edge. 3. Wolverine World Wide (WWW) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew DeGulis saying while consumer demand remains weak, there are "pockets of relative opportunity" in footwear. 4. Mirati Therapeutics (MRTX) upgraded to Overweight from Neutral at JPMorgan with analyst Anupam Rama saying recent physician feedback underscores the potential for the KRAS class as both monotherapy and as part of combination approaches, and highlights the potential for differentiation for Mirati's MRTX849 within the class. 5. Seattle Genetics (SGEN) upgraded to Buy from Neutral at Guggenheim with analyst Michael Schmidt saying he has increased conviction in the commercial potential of recently launched Tukysa in HER2+ cancers and Padcev in urothelial cancers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link

ShowHide Related Items >><<
BIG Big Lots
$24.08 /

+0.62 (+2.64%)

05/01/20 Piper Sandler
Big Lots upgraded to Overweight from Neutral at Piper Sandler
04/09/20
Fly Intel: Top five analyst upgrades
04/09/20 JPMorgan
Big Lots upgraded to Neutral from Underweight at JPMorgan
02/28/20
Fly Intel: Top five analyst downgrades
K Kellogg
$65.20 /

-0.35 (-0.53%)

05/01/20 Consumer Edge
Kellogg upgraded to Equal Weight from Underweight at Consumer Edge
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
03/18/20 Bernstein
Kellogg upgraded to Market Perform from Underperform at Bernstein
02/20/20 Buckingham
Kellogg price target lowered to $76 from $78 at Buckingham
WWW Wolverine World Wide
$19.97 /

-0.6 (-2.92%)

05/01/20 KeyBanc
Wolverine World Wide upgraded to Overweight from Sector Weight at KeyBanc
04/23/20 Susquehanna
Wolverine World Wide downgraded to Neutral at Susquehanna
04/23/20 Susquehanna
Wolverine World Wide downgraded to Neutral from Positive at Susquehanna
02/26/20 Susquehanna
Wolverine World Wide price target lowered to $33 from $37 at Susquehanna
MRTX Mirati Therapeutics
$85.04 /

+ (+0.00%)

05/01/20 JPMorgan
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential
05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
SGEN Seattle Genetics
$147.05 /

+9.77 (+7.12%)

05/01/20 Guggenheim
Guggenheim upgrades Seattle Genetics to Buy on 40% sales growth potential
05/01/20 H.C. Wainwright
Seattle Genetics price target raised to $175 from $150 at H.C. Wainwright
05/01/20 Guggenheim
Seattle Genetics upgraded to Buy from Neutral at Guggenheim
04/27/20 Piper Sandler
Seattle Genetics price target raised to $155 from $135 at Piper Sandler
Upgrade
JPMorgan upgrades Mirati Therapeutics to Overweight on MRTX849 potential » 09:05
05/01/20
05/01
09:05
05/01/20
09:05
MRTX

Mirati Therapeutics

$85.04 /

-2.54 (-2.90%)

As previously reported,…

As previously reported, JPMorgan analyst Anupam Rama upgraded Mirati Therapeutics to Overweight from Neutral with a price target of $116, up from $88. Recent physician feedback underscores the potential for the KRAS class as both monotherapy and as part of combination approaches, and highlights the potential for differentiation for Mirati's MRTX849 within the class, Rama tells investors. The rest of 2020 is "a catalyst-heavy period for the KRAS class," including a key update for MRTX849 due in the second half, the analyst added.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$85.04 /

-2.54 (-2.90%)

05/01/20 JPMorgan
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan
04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
03/30/20 Oppenheimer
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer
Upgrade
Mirati Therapeutics upgraded to Overweight from Neutral at JPMorgan » 04:41
05/01/20
05/01
04:41
05/01/20
04:41
MRTX

Mirati Therapeutics

$85.04 /

-2.54 (-2.90%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama upgraded Mirati Therapeutics to Overweight from Neutral with a $116 price target.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$85.04 /

-2.54 (-2.90%)

04/21/20 JonesTrading
Mirati selloff on short report a buying opportunity, says JonesTrading
04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
03/30/20 Oppenheimer
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer
03/12/20 JPMorgan
Mirati upgraded to Neutral into MRTX849 readout at JPMorgan
Recommendations
Mirati selloff on short report a buying opportunity, says JonesTrading » 13:33
04/21/20
04/21
13:33
04/21/20
13:33
MRTX

Mirati Therapeutics

$86.77 /

-8.67 (-9.08%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy views the selloff today in shares of Mirati Therapeutics following a widely circulated short report as a buying opportunity. The stock in afternoon trading is down 8%, or $7.36, to $88.02. The report is not based on any new data, but from reanalyzing prior data and the competitive landscape, Roy tells investors in a research note. The key driver to the stock remains the KRAS G12Ci, MRTX849, adds the analyst, who notes Mirati remains the most clinically advanced SMID cap biotech company in KRASi space. Further, Roy continues to see sitravatinib contributing towards Mirati's valuation. The analyst reiterates a Buy rating on the shares with a $130 price target.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$86.77 /

-8.67 (-9.08%)

04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
03/30/20 Oppenheimer
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer
03/12/20 JPMorgan
Mirati upgraded to Neutral into MRTX849 readout at JPMorgan
03/12/20 JPMorgan
Mirati Therapeutics upgraded to Neutral from Underweight at JPMorgan
Hot Stocks
Mirati slides as short-seller says oncology drugs 'destined for futility' » 10:28
04/21/20
04/21
10:28
04/21/20
10:28
MRTX

Mirati Therapeutics

$91.48 /

-3.96 (-4.15%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) is under pressure on Tuesday after Kerrisdale Capital said it is short shares of the company and that investors are "ignoring KRASi risks." Further, the short-seller argued that while most of Mirati's value is tied up "in the dream of '849," investors are still ascribing significant value to the company's other oncology compound, sitravatinib, which Kerrisdale expects will fail the multiple combination trials Mirati is now conducting. INVESTORS IGNORING KRASI RISKS: In a newly published report, Kerrisdale Capital said it is short shares of Mirati Therapeutics, a clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849, is a small-molecule KRAS inhibitor. "While most of Mirati's value is tied up in the dream of '849, investors are still ascribing significant value to Mirati's other oncology compound, sitravatinib. But given sitravatinib's almost complete failure as a single agent, we're confident the drug will fail the multiple combination trials Mirati is now conducting. Bolstering our confidence are the weak data, a barely believable mechanism of action, and a sloppy trial riddled with data discrepancies and irregularities that are easily identified in Mirati's sitravatinib presentations. With both '849 and Sitravatinib destined for futility, and its pipeline practically non-existent, Mirati investors will soon discover that the only thing the company can successfully inhibit is their performance," the report reads. "Mirati's opportunity set is therefore best described as an extremely low-percentage chance of attaining a low-percentage share of a $600-800 million market circa 2025. What's that worth right now? A small fraction of $4.6 billion. Investors who have gambled on the M&A prospects of what amounts to a single dead-end compound will soon find out they're on the wrong path." PRICE ACTION: In morning trading, shares of Mirati have dropped almost 5% to $91.05. Reference Link

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$91.48 /

-3.96 (-4.15%)

04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
03/30/20 Oppenheimer
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer
03/12/20 JPMorgan
Mirati upgraded to Neutral into MRTX849 readout at JPMorgan
03/12/20 JPMorgan
Mirati Therapeutics upgraded to Neutral from Underweight at JPMorgan
Periodicals
Mirati worth 'a fraction' of $4.5B 'at best,' short-seller Kerrisdale says » 10:08
04/21/20
04/21
10:08
04/21/20
10:08
MRTX

Mirati Therapeutics

$96.01 /

+0.57 (+0.60%)

Kerrisdale Capital said…

Kerrisdale Capital said in a series of tweets: "We're short $MRTX. Report available at kerr.co/mrtx. Mirati's multi-billion-dollar valuation rests primarily on its KRAS(G12C) inhibitor, MRTX-849, and to a lesser extent, multi-kinase inhibitor sitravatinib. Both are dead end drugs...At more than $4.5bn, Mirati's valuation assumes great clinical success & maybe some M&A. But the future of its 2 drugs is bleaker than ever, not to mention G12C competition & 2nd-gen KRASi looming. At best $MRTX is worth a fraction of $4.5bn. At worst, it's a zero." Reference Link

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$96.01 /

+0.57 (+0.60%)

04/16/20 Goldman Sachs
Mirati Therapeutics initiated with a Buy at Goldman Sachs
03/30/20 Oppenheimer
Mirati Therapeutics price target lowered to $105 from $129 at Oppenheimer
03/12/20 JPMorgan
Mirati upgraded to Neutral into MRTX849 readout at JPMorgan
03/12/20 JPMorgan
Mirati Therapeutics upgraded to Neutral from Underweight at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.